Additionally, the effects of Rnls deletion were reproduced by oral administration of a previously U.S. Food and Drug Administration (FDA)-approved drug, pargyline, presenting a potential pharmacological agent that could be repurposed as a preventive therapeutic for T1D [31]. Here, RNLS is linked to type 1 diabetes mellitus.